Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inventiva...
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Inventiva, with a price target of $26.00. The company’s shares closed yesterday at $5.53.Elevate Your Investing...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Quest Diagnostics (DGX – Research Report) and Inventiva (IVA – Research Report).Elevate Your Investing Strategy: Take...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on PepGen Inc. (PEPG – Research Report) and Inventiva (IVA – Research Report).Elevate Your Investing Strategy: Take advantage...
In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva, with a price target of $20.00. The company’s shares closed yesterday at $6.24.Elevate Your Investing...
In a report released today, Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva, with a price target of $20.00. The company’s shares closed yesterday at $5.91.Elevate Your Investing...
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Cash position2 at €87.2 m as of June 30, 2022Revenues of €0.1 m in H1 2022Inventiva entered into a finance loan and a warrant agreement for up to €50...
Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical...
The Phase IIa Proof-of-Concept study is designed to assess the safety and efficacy of lanifibranor in combination with the SGLT2 inhibitor empagliflozin...